<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00184600</url>
  </required_header>
  <id_info>
    <org_study_id>NN304-1613</org_study_id>
    <secondary_id>2004-000514-38</secondary_id>
    <nct_id>NCT00184600</nct_id>
  </id_info>
  <brief_title>Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes</brief_title>
  <acronym>4T</acronym>
  <official_title>A 36-month, Multi-centre, Open-label, Randomised, Parallel-group Trial Comparing the Safety, Efficacy and Durability of Adding a Basal Insulin Versus a Twice Daily Insulin Mixture Versus a Meal-time Rapid-Acting Insulin in Subjects With Type 2 Diabetes Inadequately Controlled on Therapy With Oral Agents, and Assessing the Requirement for More Complex Insulin Regimens to Achieve and Maintain Glycaemic Control, Their Efficacy and Durability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe.

      The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood
      glucose levels) of insulin detemir, insulin aspart and biphasic insulin aspart 30, when added
      to current OAD (oral anti-diabetic drug) treatment in subjects with type 2 diabetes and to
      verify the safety of use (number and severity of episodes of hypoglycaemia, body weight and
      side effects).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c (Glycosylated Haemoglobin) at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>HbA1c values offer evidence of the efficacy and durability of the insulin regimens.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c (Glycosylated Haemoglobin) at Month 36</measure>
    <time_frame>Baseline, Month 36</time_frame>
    <description>HbA1c values offer evidence of the efficacy and durability of the insulin regimens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants (Total Participants and the Subset of Participants Who Did Not Have an Hypoglycaemic Episode) Achieving a Month 12 Value in HbA1c Below or Equal to 6.5%</measure>
    <time_frame>Month 12</time_frame>
    <description>Two participant counts are listed. The first is the percentage of total participants who achieved the target (HbA1c below or equal to 6.5%) at Month 12. The second is the percentage of subset of participants who achieved the target and did not have either minor or major hypoglycaemic episode within the four weeks prior to the month 12 exam. Minor hypoglycaemic episode is an episode in which the participant was able to treat her/himself and plasma glucose was below 3.1 mmol/L (56 mg/dL). Major hypoglycaemic episode is an episode in which the participant was unable to treat her/himself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Month 36 Value in HbA1c Below or Equal to 6.5%</measure>
    <time_frame>Month 36</time_frame>
    <description>Percentage of participants who achieved the target (HbA1c below or equal to 6.5%) at Month 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hypoglycaemic Events Per Participant Per Year at Month 12 for All Participants and the Subset Who Achieved Target HbA1c Below or Equal to 6.5%</measure>
    <time_frame>Month 12</time_frame>
    <description>Rate of hypoglycaemic events was calculated as the median number of events per participant per year, defined as grade 1 (symptoms only), 2 (minor) and 3 (major). Symptoms only if self-measured plasma glucose level of 3.1 mmol/L (56 mg/dL) or more. Minor (grade 2) if able to treat her/himself and plasma glucose was below 3.1 mmol/L (56 mg/dL). Major (grade 3) if unable to treat her/himself. Rates are reported for all participants and for the subset of participants who achieved target HbA1c below or equal to 6.5%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hypoglycaemic Events Per Participant Per Year at Month 36 for All Participants and the Subset Who Achieved Target HbA1c Below or Equal to 6.5%</measure>
    <time_frame>Month 36</time_frame>
    <description>Rate of hypoglycaemic events was calculated as the median number of events per participant per year, defined as grade 1 (symptoms only), 2 (minor) and 3 (major). Symptoms only if self-measured plasma glucose level of 3.1 mmol/L (56 mg/dL) or more. Minor (grade 2) if able to treat her/himself and plasma glucose was below 3.1 mmol/L (56 mg/dL). Major (grade 3) if unable to treat her/himself. Rates are reported for all participants and for the subset of participants who achieved target HbA1c below or equal to 6.5%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Required A Second Insulin Therapy by Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Percentage of participants who required a second insulin formulation to be added to their treatment. This outcome offers evidence to the efficacy and durability of the insulin regimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Required A Second Insulin Therapy by Month 36</measure>
    <time_frame>Month 36</time_frame>
    <description>Percentage of participants who required a second insulin formulation to be added to their treatment. This outcome offers evidence to the efficacy and durability of the insulin regimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Month 12</measure>
    <time_frame>Week 0 (baseline), month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Month 36</measure>
    <time_frame>Week 0 (baseline), month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Eight-point Capillary Plasma Glucose Profiles (Self-measured) at 12 Months</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>For each visit and telephone contact, participants were asked to perform in advance three capillary glucose profiles (using blood glucose metre provided for the trial) obtained before breakfast and before the evening meal for participants in the biphasic and basal groups and before meals and two hours after meals and at bedtime in the prandial group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Eight-point Capillary Plasma Glucose Profiles (Self-measured) at 36 Months</measure>
    <time_frame>Baseline, month 36</time_frame>
    <description>For each visit and telephone contact, participants were asked to perform in advance three capillary glucose profiles (using blood glucose metre provided for the trial) obtained before breakfast and before the evening meal for participants in the biphasic and basal groups and before meals and two hours after meals and at bedtime in the prandial group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by the EuroQol Group 5-Dimension Self-Report Questionnaire Score (EQ5D) at 12 Months</measure>
    <time_frame>Month 12</time_frame>
    <description>The EuroQol Group 5-Dimension Self-Report Questionnaire score (EQ5D) is a standardised instrument for use as a measure of health outcome in medical research. Responses can be used to generate a single numerical value associated with a given health state. The scale of values is graded from -0.59 to 1.00, with lower scores indicating a poorer health status. A score of 0 represents no quality of life and scores less than 0 represent states perceived by the respondent to be worse than death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by the EuroQol Group 5-Dimension Self-Report Questionnaire Score (EQ5D) at 36 Months</measure>
    <time_frame>Month 36</time_frame>
    <description>The EuroQol Group 5-Dimension Self-Report Questionnaire score (EQ5D) is a standardised instrument for use as a measure of health outcome in medical research. Responses can be used to generate a single numerical value associated with a given health state. The scale of values is graded from -0.59 to 1.00, with lower scores indicating a poorer health status. A score of 0 represents no quality of life and scores less than 0 represent states perceived by the respondent to be worse than death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Having an 'Other' Adverse Event</measure>
    <time_frame>Up to month 37 (36 months of treatment plus 1 month follow-up)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">708</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin detemir (basal insulin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin aspart (prandial insulin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biphasic insulin aspart 30 (biphasic insulin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart</intervention_name>
    <description>Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart</description>
    <arm_group_label>Insulin aspart (prandial insulin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin detemir</intervention_name>
    <description>Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart</description>
    <arm_group_label>Insulin detemir (basal insulin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin aspart</intervention_name>
    <description>Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, twice daily plus option for insulin detemir</description>
    <arm_group_label>Biphasic insulin aspart 30 (biphasic insulin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Insulin naive

          -  On OAD treatment for at least 4 months with metformin, a sulphonylurea or a
             combination

          -  Body Mass Index (BMI) below or equal to 40.0 kg/m2

          -  HbA1c (glycosylated haemoglobin): 7.0%-10% (both inclusive)

        Exclusion Criteria:

          -  Proliferative retinopathy

          -  Recurrent major hypoglycaemia

          -  Cardial problems

          -  Uncontrolled hypertension

          -  Impaired hepatic or renal function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 15</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 1LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Addlestone</city>
        <zip>KT15 2BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Airdrie</city>
        <zip>ML6 0JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ashton-Under-Lyne</city>
        <zip>OL6 9RW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ayr</city>
        <zip>KA6 6DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT37 9RH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 78B</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berkshire</city>
        <zip>RG7 3SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B71 4HJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bury St Edmunds</city>
        <zip>IP30 9QU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Colchester</city>
        <zip>CO4 5JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Coventry</city>
        <zip>CV1 4FH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Crawley</city>
        <zip>RH10 7DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Derby</city>
        <zip>DE22 3DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5AX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gillingham</city>
        <zip>ME7 5NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Haywards Heath</city>
        <zip>RH16 4EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Headington</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>High Wycombe</city>
        <zip>HP11 2TZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kettering</city>
        <zip>NN16 8UZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Leicester</city>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Livingstone</city>
        <zip>EH54 6PP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <zip>N19 3UA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 0JE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M41 5SL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Middlesborough</city>
        <zip>TS3 4BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Newcastle</city>
        <zip>NE29 0LR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Newcastle</city>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <zip>NR4 7UZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Northampton</city>
        <zip>NN1 5BD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <zip>PL8 8DQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rugby</city>
        <zip>CV22 5PX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Skipton</city>
        <zip>BD23 1EU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stevenage</city>
        <zip>SG1 4AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Torquay</city>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Welwyn Garden City</city>
        <zip>AL7 4HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Whiston</city>
        <zip>L35 5DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wirral, Merseyside</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK; 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009 Oct 29;361(18):1736-47. doi: 10.1056/NEJMoa0905479. Epub 2009 Oct 22. Erratum in: N Engl J Med. 2010 Nov 18;363(21):2078.</citation>
    <PMID>19850703</PMID>
  </results_reference>
  <results_reference>
    <citation>Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007 Oct 25;357(17):1716-30. Epub 2007 Sep 21.</citation>
    <PMID>17890232</PMID>
  </results_reference>
  <results_reference>
    <citation>Jenkins N, Hallowell N, Farmer AJ, Holman RR, Lawton J. Participants' experiences of intensifying insulin therapy during the Treating to Target in Type 2 Diabetes (4-T) trial: qualitative interview study. Diabet Med. 2011 May;28(5):543-8. doi: 10.1111/j.1464-5491.2010.03200.x.</citation>
    <PMID>21480965</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>May 10, 2011</results_first_submitted>
  <results_first_submitted_qc>June 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 25, 2011</results_first_posted>
  <last_update_submitted>January 26, 2017</last_update_submitted>
  <last_update_submitted_qc>January 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>58 sites across the United Kingdom and Ireland. Recruitment period: November 2004-August 2006</recruitment_details>
      <pre_assignment_details>Eligible subjects continued their current oral anti-diabetic drug (OAD) treatment (metformin and/or sulphonylurea) without changing the dose throughout the trial. Subjects were asked not to alter their current diet and activities throughout the trial unless clinically necessary. Subjects fasted from 22:00 the evening prior to randomisation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Insulin Detemir (Basal Insulin)</title>
          <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen</description>
        </group>
        <group group_id="P2">
          <title>Insulin Aspart (Prandial Insulin)</title>
          <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen</description>
        </group>
        <group group_id="P3">
          <title>Biphasic Insulin Aspart 30 (Biphasic Insulin)</title>
          <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="234"/>
                <participants group_id="P2" count="239"/>
                <participants group_id="P3" count="235"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="188"/>
                <participants group_id="P3" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Insulin Detemir (Basal Insulin)</title>
          <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen</description>
        </group>
        <group group_id="B2">
          <title>Insulin Aspart (Prandial Insulin)</title>
          <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen</description>
        </group>
        <group group_id="B3">
          <title>Biphasic Insulin Aspart 30 (Biphasic Insulin)</title>
          <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="234"/>
            <count group_id="B2" value="239"/>
            <count group_id="B3" value="235"/>
            <count group_id="B4" value="708"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.87" spread="9.97"/>
                    <measurement group_id="B2" value="61.60" spread="10.54"/>
                    <measurement group_id="B3" value="61.67" spread="8.93"/>
                    <measurement group_id="B4" value="61.7" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="254"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="159"/>
                    <measurement group_id="B4" value="454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                    <measurement group_id="B2" value="214"/>
                    <measurement group_id="B3" value="221"/>
                    <measurement group_id="B4" value="653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian / Asian British</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black / Black British</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking</title>
          <description>Identifying participants as smokers/non-smokers</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non Smoker, Never Smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oral Anti-Diabetic Drugs (OADs)</title>
          <description>Identifying which OAD (oral anti-diabetic drug) treatment the participant is on</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sulphonylurea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin + Sulphonylurea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="227"/>
                    <measurement group_id="B3" value="221"/>
                    <measurement group_id="B4" value="672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetic complication, Retinopathy</title>
          <description>Diabetic complication at baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="201"/>
                    <measurement group_id="B4" value="586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetic complication, Neuropathy</title>
          <description>Diabetic complication at baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="194"/>
                    <measurement group_id="B4" value="573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetic complication, Nephropathy</title>
          <description>Diabetic complication at baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="214"/>
                    <measurement group_id="B4" value="640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetic complication, Macroaniopathy</title>
          <description>Diabetic complication at baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                    <measurement group_id="B2" value="197"/>
                    <measurement group_id="B3" value="183"/>
                    <measurement group_id="B4" value="570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes</title>
          <description>Number of years since diagnosis</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9" spread="5.13" lower_limit="6" upper_limit="12"/>
                    <measurement group_id="B2" value="9" spread="5.54" lower_limit="6" upper_limit="14"/>
                    <measurement group_id="B3" value="9" spread="5.23" lower_limit="6" upper_limit="12"/>
                    <measurement group_id="B4" value="9" lower_limit="6" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol</title>
          <description>Number of units consumed weekly. One unit of alcohol = 10ml pure alcohol by volume or 8g by weight.</description>
          <units>units</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" spread="9.16" lower_limit="2" upper_limit="12"/>
                    <measurement group_id="B2" value="5" spread="7.88" lower_limit="2" upper_limit="12"/>
                    <measurement group_id="B3" value="6" spread="9.61" lower_limit="2" upper_limit="12"/>
                    <measurement group_id="B4" value="5" lower_limit="2" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>Weight of participants</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.52" spread="16.25"/>
                    <measurement group_id="B2" value="84.92" spread="14.43"/>
                    <measurement group_id="B3" value="86.91" spread="16.82"/>
                    <measurement group_id="B4" value="85.8" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI of participants</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.82" spread="4.59"/>
                    <measurement group_id="B2" value="29.74" spread="4.51"/>
                    <measurement group_id="B3" value="30.34" spread="4.73"/>
                    <measurement group_id="B4" value="29.8" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist</title>
          <description>Waist circumference of participants</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Men</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104" spread="12"/>
                    <measurement group_id="B2" value="102" spread="11"/>
                    <measurement group_id="B3" value="104" spread="12"/>
                    <measurement group_id="B4" value="103" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Women</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97" spread="12"/>
                    <measurement group_id="B2" value="100" spread="11"/>
                    <measurement group_id="B3" value="98" spread="13"/>
                    <measurement group_id="B4" value="98" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eight-point Capillary Plasma Glucose Profiles</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>All time pointsexcluding 3 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196" spread="43"/>
                    <measurement group_id="B2" value="200" spread="49"/>
                    <measurement group_id="B3" value="202" spread="47"/>
                    <measurement group_id="B4" value="200" spread="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fasting plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171" spread="47"/>
                    <measurement group_id="B2" value="173" spread="49"/>
                    <measurement group_id="B3" value="175" spread="50"/>
                    <measurement group_id="B4" value="173" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postprandial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223" spread="50"/>
                    <measurement group_id="B2" value="227" spread="56"/>
                    <measurement group_id="B3" value="229" spread="54"/>
                    <measurement group_id="B4" value="227" spread="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 3 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164" spread="56"/>
                    <measurement group_id="B2" value="164" spread="59"/>
                    <measurement group_id="B3" value="171" spread="58"/>
                    <measurement group_id="B4" value="166" spread="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HbA1c (Glycosylated Haemoglobin) at Month 12</title>
        <description>HbA1c values offer evidence of the efficacy and durability of the insulin regimens.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir (Basal Insulin)</title>
            <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart (Prandial Insulin)</title>
            <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O3">
            <title>Biphasic Insulin Aspart 30 (Biphasic Insulin)</title>
            <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c (Glycosylated Haemoglobin) at Month 12</title>
          <description>HbA1c values offer evidence of the efficacy and durability of the insulin regimens.</description>
          <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
          <units>percentage (%) of total haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.45" spread="0.80"/>
                    <measurement group_id="O2" value="8.55" spread="0.78"/>
                    <measurement group_id="O3" value="8.63" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.64" spread="0.96"/>
                    <measurement group_id="O2" value="7.20" spread="1.06"/>
                    <measurement group_id="O3" value="7.33" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HbA1c (Glycosylated Haemoglobin) at Month 36</title>
        <description>HbA1c values offer evidence of the efficacy and durability of the insulin regimens.</description>
        <time_frame>Baseline, Month 36</time_frame>
        <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir (Basal Insulin)</title>
            <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart (Prandial Insulin)</title>
            <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O3">
            <title>Biphasic Insulin Aspart 30 (Biphasic Insulin)</title>
            <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c (Glycosylated Haemoglobin) at Month 36</title>
          <description>HbA1c values offer evidence of the efficacy and durability of the insulin regimens.</description>
          <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
          <units>percentage (%) of total haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.45" spread="0.80"/>
                    <measurement group_id="O2" value="8.55" spread="0.78"/>
                    <measurement group_id="O3" value="8.63" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.11" spread="1.13"/>
                    <measurement group_id="O2" value="7.04" spread="1.17"/>
                    <measurement group_id="O3" value="7.22" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants (Total Participants and the Subset of Participants Who Did Not Have an Hypoglycaemic Episode) Achieving a Month 12 Value in HbA1c Below or Equal to 6.5%</title>
        <description>Two participant counts are listed. The first is the percentage of total participants who achieved the target (HbA1c below or equal to 6.5%) at Month 12. The second is the percentage of subset of participants who achieved the target and did not have either minor or major hypoglycaemic episode within the four weeks prior to the month 12 exam. Minor hypoglycaemic episode is an episode in which the participant was able to treat her/himself and plasma glucose was below 3.1 mmol/L (56 mg/dL). Major hypoglycaemic episode is an episode in which the participant was unable to treat her/himself.</description>
        <time_frame>Month 12</time_frame>
        <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir (Basal Insulin)</title>
            <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart (Prandial Insulin)</title>
            <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O3">
            <title>Biphasic Insulin Aspart 30 (Biphasic Insulin)</title>
            <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants (Total Participants and the Subset of Participants Who Did Not Have an Hypoglycaemic Episode) Achieving a Month 12 Value in HbA1c Below or Equal to 6.5%</title>
          <description>Two participant counts are listed. The first is the percentage of total participants who achieved the target (HbA1c below or equal to 6.5%) at Month 12. The second is the percentage of subset of participants who achieved the target and did not have either minor or major hypoglycaemic episode within the four weeks prior to the month 12 exam. Minor hypoglycaemic episode is an episode in which the participant was able to treat her/himself and plasma glucose was below 3.1 mmol/L (56 mg/dL). Major hypoglycaemic episode is an episode in which the participant was unable to treat her/himself.</description>
          <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total participants who achieved target</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1"/>
                    <measurement group_id="O2" value="23.9"/>
                    <measurement group_id="O3" value="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subset who achieved target, n=18, 50, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9"/>
                    <measurement group_id="O2" value="43.9"/>
                    <measurement group_id="O3" value="52.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Month 36 Value in HbA1c Below or Equal to 6.5%</title>
        <description>Percentage of participants who achieved the target (HbA1c below or equal to 6.5%) at Month 36</description>
        <time_frame>Month 36</time_frame>
        <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir (Basal Insulin)</title>
            <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart (Prandial Insulin)</title>
            <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O3">
            <title>Biphasic Insulin Aspart 30 (Biphasic Insulin)</title>
            <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Month 36 Value in HbA1c Below or Equal to 6.5%</title>
          <description>Percentage of participants who achieved the target (HbA1c below or equal to 6.5%) at Month 36</description>
          <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2"/>
                    <measurement group_id="O2" value="44.8"/>
                    <measurement group_id="O3" value="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hypoglycaemic Events Per Participant Per Year at Month 12 for All Participants and the Subset Who Achieved Target HbA1c Below or Equal to 6.5%</title>
        <description>Rate of hypoglycaemic events was calculated as the median number of events per participant per year, defined as grade 1 (symptoms only), 2 (minor) and 3 (major). Symptoms only if self-measured plasma glucose level of 3.1 mmol/L (56 mg/dL) or more. Minor (grade 2) if able to treat her/himself and plasma glucose was below 3.1 mmol/L (56 mg/dL). Major (grade 3) if unable to treat her/himself. Rates are reported for all participants and for the subset of participants who achieved target HbA1c below or equal to 6.5%.</description>
        <time_frame>Month 12</time_frame>
        <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir (Basal Insulin)</title>
            <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart (Prandial Insulin)</title>
            <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O3">
            <title>Biphasic Insulin Aspart 30 (Biphasic Insulin)</title>
            <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hypoglycaemic Events Per Participant Per Year at Month 12 for All Participants and the Subset Who Achieved Target HbA1c Below or Equal to 6.5%</title>
          <description>Rate of hypoglycaemic events was calculated as the median number of events per participant per year, defined as grade 1 (symptoms only), 2 (minor) and 3 (major). Symptoms only if self-measured plasma glucose level of 3.1 mmol/L (56 mg/dL) or more. Minor (grade 2) if able to treat her/himself and plasma glucose was below 3.1 mmol/L (56 mg/dL). Major (grade 3) if unable to treat her/himself. Rates are reported for all participants and for the subset of participants who achieved target HbA1c below or equal to 6.5%.</description>
          <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
          <units>hypoglycaemic events/participant/year</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All participants, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="8.0" lower_limit="3.0" upper_limit="19.2"/>
                    <measurement group_id="O3" value="5.0" lower_limit="1.0" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All participants, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="8.0" lower_limit="2.9" upper_limit="17.7"/>
                    <measurement group_id="O3" value="3.9" lower_limit="1.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All participants, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All participants, Grade 2 or 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="8.0" lower_limit="3.0" upper_limit="18.0"/>
                    <measurement group_id="O3" value="3.9" lower_limit="1.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Achieved HbA1c target, Grade 1, n=18, 50, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="0" upper_limit="5.2"/>
                    <measurement group_id="O2" value="7.8" lower_limit="2.0" upper_limit="21.0"/>
                    <measurement group_id="O3" value="5.4" lower_limit="1.5" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Achieved HbA1c target, Grade 2, n=18, 50, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="0" upper_limit="4.9"/>
                    <measurement group_id="O2" value="8.0" lower_limit="2.0" upper_limit="20.0"/>
                    <measurement group_id="O3" value="4.0" lower_limit="1.5" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Achieved HbA1c target, Grade 3, n=18, 50, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Achieved HbA1c target, Grade 2 or 3, n=18, 50, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="0" upper_limit="4.9"/>
                    <measurement group_id="O2" value="8.7" lower_limit="2.9" upper_limit="20.0"/>
                    <measurement group_id="O3" value="4.0" lower_limit="1.9" upper_limit="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hypoglycaemic Events Per Participant Per Year at Month 36 for All Participants and the Subset Who Achieved Target HbA1c Below or Equal to 6.5%</title>
        <description>Rate of hypoglycaemic events was calculated as the median number of events per participant per year, defined as grade 1 (symptoms only), 2 (minor) and 3 (major). Symptoms only if self-measured plasma glucose level of 3.1 mmol/L (56 mg/dL) or more. Minor (grade 2) if able to treat her/himself and plasma glucose was below 3.1 mmol/L (56 mg/dL). Major (grade 3) if unable to treat her/himself. Rates are reported for all participants and for the subset of participants who achieved target HbA1c below or equal to 6.5%.</description>
        <time_frame>Month 36</time_frame>
        <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir (Basal Insulin)</title>
            <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart (Prandial Insulin)</title>
            <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O3">
            <title>Biphasic Insulin Aspart 30 (Biphasic Insulin)</title>
            <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hypoglycaemic Events Per Participant Per Year at Month 36 for All Participants and the Subset Who Achieved Target HbA1c Below or Equal to 6.5%</title>
          <description>Rate of hypoglycaemic events was calculated as the median number of events per participant per year, defined as grade 1 (symptoms only), 2 (minor) and 3 (major). Symptoms only if self-measured plasma glucose level of 3.1 mmol/L (56 mg/dL) or more. Minor (grade 2) if able to treat her/himself and plasma glucose was below 3.1 mmol/L (56 mg/dL). Major (grade 3) if unable to treat her/himself. Rates are reported for all participants and for the subset of participants who achieved target HbA1c below or equal to 6.5%.</description>
          <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
          <units>hypoglycaemic events/participant/year</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All participants, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.3" upper_limit="3.0"/>
                    <measurement group_id="O2" value="5.7" lower_limit="4.3" upper_limit="7.2"/>
                    <measurement group_id="O3" value="3.8" lower_limit="3.3" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All participants, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.3" upper_limit="2.0"/>
                    <measurement group_id="O2" value="5.5" lower_limit="4.3" upper_limit="6.9"/>
                    <measurement group_id="O3" value="3.0" lower_limit="2.3" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All participants, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All participants, Grade 2 or 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.3" upper_limit="2.0"/>
                    <measurement group_id="O2" value="5.7" lower_limit="4.3" upper_limit="7.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="2.3" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Achieved HbA1c target, Grade 1, n=73, 70, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.7" upper_limit="3.7"/>
                    <measurement group_id="O2" value="5.7" lower_limit="3.5" upper_limit="7.7"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.7" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Achieved HbA1c target, Grade 2, n=73, 70, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.3" upper_limit="2.7"/>
                    <measurement group_id="O2" value="5.3" lower_limit="3.8" upper_limit="8.0"/>
                    <measurement group_id="O3" value="2.7" lower_limit="1.7" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Achieved HbA1c target, Grade 3, n=73, 70, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Achieved HbA1c target, Grade 2 or 3, n=73, 70, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.3" upper_limit="2.7"/>
                    <measurement group_id="O2" value="5.5" lower_limit="4.0" upper_limit="8.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.7" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Required A Second Insulin Therapy by Month 12</title>
        <description>Percentage of participants who required a second insulin formulation to be added to their treatment. This outcome offers evidence to the efficacy and durability of the insulin regimens.</description>
        <time_frame>Month 12</time_frame>
        <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir (Basal Insulin)</title>
            <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart (Prandial Insulin)</title>
            <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O3">
            <title>Biphasic Insulin Aspart 30 (Biphasic Insulin)</title>
            <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Required A Second Insulin Therapy by Month 12</title>
          <description>Percentage of participants who required a second insulin formulation to be added to their treatment. This outcome offers evidence to the efficacy and durability of the insulin regimens.</description>
          <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="4.2"/>
                    <measurement group_id="O3" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Required A Second Insulin Therapy by Month 36</title>
        <description>Percentage of participants who required a second insulin formulation to be added to their treatment. This outcome offers evidence to the efficacy and durability of the insulin regimens.</description>
        <time_frame>Month 36</time_frame>
        <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir (Basal Insulin)</title>
            <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart (Prandial Insulin)</title>
            <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O3">
            <title>Biphasic Insulin Aspart 30 (Biphasic Insulin)</title>
            <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Required A Second Insulin Therapy by Month 36</title>
          <description>Percentage of participants who required a second insulin formulation to be added to their treatment. This outcome offers evidence to the efficacy and durability of the insulin regimens.</description>
          <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Month 12</title>
        <time_frame>Week 0 (baseline), month 12</time_frame>
        <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir (Basal Insulin)</title>
            <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart (Prandial Insulin)</title>
            <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O3">
            <title>Biphasic Insulin Aspart 30 (Biphasic Insulin)</title>
            <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Month 12</title>
          <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="4.2"/>
                    <measurement group_id="O2" value="5.7" spread="4.6"/>
                    <measurement group_id="O3" value="4.7" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Month 36</title>
        <time_frame>Week 0 (baseline), month 36</time_frame>
        <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir (Basal Insulin)</title>
            <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart (Prandial Insulin)</title>
            <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O3">
            <title>Biphasic Insulin Aspart 30 (Biphasic Insulin)</title>
            <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Month 36</title>
          <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0.5"/>
                    <measurement group_id="O2" value="6.4" spread="0.5"/>
                    <measurement group_id="O3" value="5.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Eight-point Capillary Plasma Glucose Profiles (Self-measured) at 12 Months</title>
        <description>For each visit and telephone contact, participants were asked to perform in advance three capillary glucose profiles (using blood glucose metre provided for the trial) obtained before breakfast and before the evening meal for participants in the biphasic and basal groups and before meals and two hours after meals and at bedtime in the prandial group.</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir (Basal Insulin)</title>
            <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart (Prandial Insulin)</title>
            <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O3">
            <title>Biphasic Insulin Aspart 30 (Biphasic Insulin)</title>
            <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Eight-point Capillary Plasma Glucose Profiles (Self-measured) at 12 Months</title>
          <description>For each visit and telephone contact, participants were asked to perform in advance three capillary glucose profiles (using blood glucose metre provided for the trial) obtained before breakfast and before the evening meal for participants in the biphasic and basal groups and before meals and two hours after meals and at bedtime in the prandial group.</description>
          <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All timepoints excluding 3am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43" spread="43"/>
                    <measurement group_id="O2" value="-65" spread="43"/>
                    <measurement group_id="O3" value="-59" spread="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fasting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59" spread="52"/>
                    <measurement group_id="O2" value="-23" spread="49"/>
                    <measurement group_id="O3" value="-45" spread="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postprandial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47" spread="54"/>
                    <measurement group_id="O2" value="-83" spread="54"/>
                    <measurement group_id="O3" value="-68" spread="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40" spread="70"/>
                    <measurement group_id="O2" value="-34" spread="59"/>
                    <measurement group_id="O3" value="-52" spread="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Eight-point Capillary Plasma Glucose Profiles (Self-measured) at 36 Months</title>
        <description>For each visit and telephone contact, participants were asked to perform in advance three capillary glucose profiles (using blood glucose metre provided for the trial) obtained before breakfast and before the evening meal for participants in the biphasic and basal groups and before meals and two hours after meals and at bedtime in the prandial group.</description>
        <time_frame>Baseline, month 36</time_frame>
        <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir (Basal Insulin)</title>
            <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart (Prandial Insulin)</title>
            <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O3">
            <title>Biphasic Insulin Aspart 30 (Biphasic Insulin)</title>
            <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Eight-point Capillary Plasma Glucose Profiles (Self-measured) at 36 Months</title>
          <description>For each visit and telephone contact, participants were asked to perform in advance three capillary glucose profiles (using blood glucose metre provided for the trial) obtained before breakfast and before the evening meal for participants in the biphasic and basal groups and before meals and two hours after meals and at bedtime in the prandial group.</description>
          <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All timepoints excluding 3am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-58" spread="43"/>
                    <measurement group_id="O2" value="-67" spread="47"/>
                    <measurement group_id="O3" value="-56" spread="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fasting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47" spread="49"/>
                    <measurement group_id="O2" value="-49" spread="45"/>
                    <measurement group_id="O3" value="-50" spread="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postprandial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67" spread="50"/>
                    <measurement group_id="O2" value="-85" spread="59"/>
                    <measurement group_id="O3" value="-61" spread="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45" spread="77"/>
                    <measurement group_id="O2" value="-27" spread="70"/>
                    <measurement group_id="O3" value="-38" spread="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by the EuroQol Group 5-Dimension Self-Report Questionnaire Score (EQ5D) at 12 Months</title>
        <description>The EuroQol Group 5-Dimension Self-Report Questionnaire score (EQ5D) is a standardised instrument for use as a measure of health outcome in medical research. Responses can be used to generate a single numerical value associated with a given health state. The scale of values is graded from -0.59 to 1.00, with lower scores indicating a poorer health status. A score of 0 represents no quality of life and scores less than 0 represent states perceived by the respondent to be worse than death.</description>
        <time_frame>Month 12</time_frame>
        <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir (Basal Insulin)</title>
            <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart (Prandial Insulin)</title>
            <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O3">
            <title>Biphasic Insulin Aspart 30 (Biphasic Insulin)</title>
            <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by the EuroQol Group 5-Dimension Self-Report Questionnaire Score (EQ5D) at 12 Months</title>
          <description>The EuroQol Group 5-Dimension Self-Report Questionnaire score (EQ5D) is a standardised instrument for use as a measure of health outcome in medical research. Responses can be used to generate a single numerical value associated with a given health state. The scale of values is graded from -0.59 to 1.00, with lower scores indicating a poorer health status. A score of 0 represents no quality of life and scores less than 0 represent states perceived by the respondent to be worse than death.</description>
          <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" lower_limit="0.75" upper_limit="0.81"/>
                    <measurement group_id="O2" value="0.76" lower_limit="0.73" upper_limit="0.79"/>
                    <measurement group_id="O3" value="0.76" lower_limit="0.73" upper_limit="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by the EuroQol Group 5-Dimension Self-Report Questionnaire Score (EQ5D) at 36 Months</title>
        <description>The EuroQol Group 5-Dimension Self-Report Questionnaire score (EQ5D) is a standardised instrument for use as a measure of health outcome in medical research. Responses can be used to generate a single numerical value associated with a given health state. The scale of values is graded from -0.59 to 1.00, with lower scores indicating a poorer health status. A score of 0 represents no quality of life and scores less than 0 represent states perceived by the respondent to be worse than death.</description>
        <time_frame>Month 36</time_frame>
        <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir (Basal Insulin)</title>
            <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart (Prandial Insulin)</title>
            <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O3">
            <title>Biphasic Insulin Aspart 30 (Biphasic Insulin)</title>
            <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by the EuroQol Group 5-Dimension Self-Report Questionnaire Score (EQ5D) at 36 Months</title>
          <description>The EuroQol Group 5-Dimension Self-Report Questionnaire score (EQ5D) is a standardised instrument for use as a measure of health outcome in medical research. Responses can be used to generate a single numerical value associated with a given health state. The scale of values is graded from -0.59 to 1.00, with lower scores indicating a poorer health status. A score of 0 represents no quality of life and scores less than 0 represent states perceived by the respondent to be worse than death.</description>
          <population>Intention to treat analyses (ITT) included all those randomised. Missing data was imputed by SAS Proc MI (Multiple Imputation), using the non-parametric Propensity Score method for data with monotone missing pattern under the assumption of non-normality and the Bayesian Monte Carlo Markov Chain approach for data with values missing intermittently.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" lower_limit="0.77" upper_limit="0.83"/>
                    <measurement group_id="O2" value="0.77" lower_limit="0.73" upper_limit="0.81"/>
                    <measurement group_id="O3" value="0.76" lower_limit="0.71" upper_limit="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Having an 'Other' Adverse Event</title>
        <time_frame>Up to month 37 (36 months of treatment plus 1 month follow-up)</time_frame>
        <population>Safety population consisting of all randomised participants exposed to at least one dose of trial drug(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir (Basal Insulin)</title>
            <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart (Prandial Insulin)</title>
            <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen</description>
          </group>
          <group group_id="O3">
            <title>Biphasic Insulin Aspart 30 (Biphasic Insulin)</title>
            <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Having an 'Other' Adverse Event</title>
          <population>Safety population consisting of all randomised participants exposed to at least one dose of trial drug(s).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="235"/>
                    <measurement group_id="O3" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse events were collected from the first trial-related activity once the subject had signed the informed consent, up until 28 days after the last clinic visit. Total reporting period for adverse events was 162 weeks.</time_frame>
      <desc>The safety analysis set contains all randomised subjects exposed to at least one dose of trial drug(s).</desc>
      <group_list>
        <group group_id="E1">
          <title>Insulin Detemir (Basal Insulin)</title>
          <description>Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen</description>
        </group>
        <group group_id="E2">
          <title>Insulin Aspart (Prandial Insulin)</title>
          <description>Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen</description>
        </group>
        <group group_id="E3">
          <title>Biphasic Insulin Aspart 30 (Biphasic Insulin)</title>
          <description>Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. At week 24 and thereafter, if two consecutive measurements of HbA1c were at least 8%, or one measurement of HbA1c was at least 10% the subject was deemed to have unacceptable hyperglycaemia and a second insulin formulation was added. In the second and third years, a third insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Unspecified</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="239"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pernicious anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="234"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Left ventribular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="234"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Change of bowel habit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Oesophageal food impaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Oesophageal rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pancreatic pseudocyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pancreatolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="234"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic liver disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Bronchpulmonary aspergillosis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Staphylococcal osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Stent related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Drug dispensing error</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Skull fracture base</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Wrong drug administered</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy liver</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pulse absent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Smear cervix abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="234"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="239"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic unconsciousness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Intervertebral disc compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Lower extremity mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Neuropathic arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Basosquamous carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Bladder papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Borderline ovarian tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Colon cancer stage I</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Endometrial cancer stage III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Galbladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Leiomyosarcoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage IIIB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Rectal cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Rectal cancer stage III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pneumocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Radiculitis brachial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Sensory loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Urethral meatus stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Haematospermia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Wegener's granulomatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Lichen sclerosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Penile prosthesis insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Umbilical hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial stenosis limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Unspecified</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="227" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="235" subjects_at_risk="239"/>
                <counts group_id="E3" subjects_affected="228" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="234"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="239"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="234"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="239"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="33" subjects_affected="14" subjects_at_risk="234"/>
                <counts group_id="E2" events="24" subjects_affected="16" subjects_at_risk="239"/>
                <counts group_id="E3" events="40" subjects_affected="27" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="234"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="239"/>
                <counts group_id="E3" events="20" subjects_affected="14" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="115" subjects_affected="60" subjects_at_risk="234"/>
                <counts group_id="E2" events="75" subjects_affected="53" subjects_at_risk="239"/>
                <counts group_id="E3" events="63" subjects_affected="45" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="38" subjects_affected="21" subjects_at_risk="234"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="239"/>
                <counts group_id="E3" events="19" subjects_affected="13" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="80" subjects_affected="45" subjects_at_risk="234"/>
                <counts group_id="E2" events="68" subjects_affected="44" subjects_at_risk="239"/>
                <counts group_id="E3" events="71" subjects_affected="43" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="234"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="239"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" events="49" subjects_affected="39" subjects_at_risk="234"/>
                <counts group_id="E2" events="50" subjects_affected="34" subjects_at_risk="239"/>
                <counts group_id="E3" events="46" subjects_affected="34" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Injection site mass</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="234"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="239"/>
                <counts group_id="E3" events="21" subjects_affected="16" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="38" subjects_affected="15" subjects_at_risk="234"/>
                <counts group_id="E2" events="38" subjects_affected="18" subjects_at_risk="239"/>
                <counts group_id="E3" events="27" subjects_affected="18" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="234"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="239"/>
                <counts group_id="E3" events="17" subjects_affected="6" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="234"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="239"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="234"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="239"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="84" subjects_affected="50" subjects_at_risk="234"/>
                <counts group_id="E2" events="88" subjects_affected="55" subjects_at_risk="239"/>
                <counts group_id="E3" events="89" subjects_affected="59" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="55" subjects_affected="37" subjects_at_risk="234"/>
                <counts group_id="E2" events="33" subjects_affected="29" subjects_at_risk="239"/>
                <counts group_id="E3" events="43" subjects_affected="33" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="234"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="239"/>
                <counts group_id="E3" events="20" subjects_affected="16" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="251" subjects_affected="108" subjects_at_risk="234"/>
                <counts group_id="E2" events="211" subjects_affected="97" subjects_at_risk="239"/>
                <counts group_id="E3" events="208" subjects_affected="99" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="234"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="239"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="51" subjects_affected="33" subjects_at_risk="234"/>
                <counts group_id="E2" events="51" subjects_affected="28" subjects_at_risk="239"/>
                <counts group_id="E3" events="35" subjects_affected="27" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="67" subjects_affected="32" subjects_at_risk="234"/>
                <counts group_id="E2" events="31" subjects_affected="24" subjects_at_risk="239"/>
                <counts group_id="E3" events="60" subjects_affected="30" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="234"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="239"/>
                <counts group_id="E3" events="17" subjects_affected="13" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="234"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="239"/>
                <counts group_id="E3" events="20" subjects_affected="16" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="234"/>
                <counts group_id="E2" events="32" subjects_affected="23" subjects_at_risk="239"/>
                <counts group_id="E3" events="32" subjects_affected="25" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="40" subjects_affected="31" subjects_at_risk="234"/>
                <counts group_id="E2" events="42" subjects_affected="38" subjects_at_risk="239"/>
                <counts group_id="E3" events="35" subjects_affected="28" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="234"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="239"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="234"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="239"/>
                <counts group_id="E3" events="11" subjects_affected="7" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="37" subjects_affected="30" subjects_at_risk="234"/>
                <counts group_id="E2" events="35" subjects_affected="31" subjects_at_risk="239"/>
                <counts group_id="E3" events="41" subjects_affected="36" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="28" subjects_affected="20" subjects_at_risk="234"/>
                <counts group_id="E2" events="23" subjects_affected="16" subjects_at_risk="239"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="234"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="239"/>
                <counts group_id="E3" events="18" subjects_affected="13" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="234"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="239"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="66" subjects_affected="48" subjects_at_risk="234"/>
                <counts group_id="E2" events="63" subjects_affected="51" subjects_at_risk="239"/>
                <counts group_id="E3" events="46" subjects_affected="38" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="234"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="239"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="51" subjects_affected="35" subjects_at_risk="234"/>
                <counts group_id="E2" events="55" subjects_affected="31" subjects_at_risk="239"/>
                <counts group_id="E3" events="37" subjects_affected="27" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="234"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="239"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Novo Nordisk reserves the right to not release data until specified milestones are reached. This includes the right to not release interim results of clinical trials, because that can invalidate results of the entire trial. At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

